MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-05-2025
Accuray Incorporated EBITDA 2011-2026 | ARAY
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Accuray Incorporated
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 14 M | 6.41 M | 6.91 M | 13.7 M | 28.6 M | 20.1 M | 11.1 M | 5.94 M | 8.22 M | 13.4 M | 324 K | 2.42 M | -55.1 M | -30.4 M | -20.7 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 28.6 M | -55.1 M | 1.66 M |
Quarterly EBITDA Accuray Incorporated
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -9.64 M | - | - | - | -685 K | - | - | - | 3.46 M | - | - | 2.7 M | -1.01 M | 2.85 M | -252 K | 4.04 M | 3.83 M | 9.23 M | 4.49 M | 8.26 M | 7.13 M | 11.5 M | 7.13 M | 3.66 M | -2.42 M | 7.34 M | -2.42 M | -838 K | -2.56 M | 3.31 M | -2.56 M | -977 K | 462 K | 3.99 M | 462 K | -2.82 M | -1.89 M | 4.46 M | -1.89 M | 1.88 M | -2.67 M | 8.94 M | -2.67 M | -1.59 M | -10.3 M | 6.37 M | -10.3 M | 1.48 M | -6.84 M | 9.86 M | -6.84 M | -20.1 M | -12.8 M | -8.35 M | -27.1 M | -1.35 M | -16.4 M | 9.21 M | -16.4 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 11.5 M | -27.1 M | -931 K |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Medical devices industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Abiomed
ABMD
|
254 M | - | - | $ 17.2 B |  USA |
 |
Acutus Medical
AFIB
|
-11.5 M | - | -26.83 % | $ 2.62 M | USA |
 |
Allied Healthcare Products
AHPI
|
-815 K | - | 3.58 % | $ 2.21 M | USA |
 |
Apollo Endosurgery
APEN
|
-30.2 M | - | - | $ 475 M | USA |
 |
GenMark Diagnostics, Inc.
GNMK
|
-3.98 M | - | - | $ 1.77 B | USA |
 |
Axonics Modulation Technologies
AXNX
|
-53.2 M | - | - | $ 3.31 B | USA |
 |
AxoGen
AXGN
|
3.18 M | $ 31.85 | 2.68 % | $ 1.41 B | USA |
 |
Cognyte Software Ltd.
CGNT
|
8.53 M | $ 8.97 | -1.59 % | $ 644 M |  Israel |
 |
Obalon Therapeutics, Inc.
OBLN
|
-9.8 M | - | -5.86 % | $ 30.6 M | USA |
 |
BIOLASE
BIOL
|
-15.1 M | - | -13.19 % | $ 166 K | USA |
 |
BioSig Technologies
BSGM
|
-12.7 M | - | 37.08 % | $ 85.7 M | USA |
 |
Apyx Medical Corporation
APYX
|
-16.6 M | $ 3.89 | -2.51 % | $ 135 M | USA |
 |
Alphatec Holdings
ATEC
|
-57.8 M | $ 16.95 | -4.48 % | $ 2.42 B | USA |
 |
Bio-Rad Laboratories
BIO
|
421 M | $ 312.8 | -0.23 % | $ 8.83 B | USA |
 |
CONMED Corporation
CNMD
|
217 M | $ 41.19 | -0.91 % | $ 1.27 B | USA |
 |
EDAP TMS S.A.
EDAP
|
-18 M | $ 3.69 | -9.12 % | $ 138 M |  France |
 |
Bruker Corporation
BRKR
|
437 M | $ 50.26 | 3.85 % | $ 7.49 K | USA |
 |
Boston Scientific Corporation
BSX
|
3.87 B | $ 91.09 | 3.43 % | $ 134 B | USA |
 |
Conformis
CFMS
|
-42.2 M | - | - | $ 16.4 M | USA |
 |
Abbott Laboratories
ABT
|
8.16 B | $ 121.01 | -0.61 % | $ 211 B | USA |
 |
Cardiovascular Systems
CSII
|
-32.1 M | - | 0.15 % | $ 844 M | USA |
 |
Cutera
CUTR
|
-148 M | - | -10.19 % | $ 1.99 M | USA |
 |
CryoLife, Inc.
CRY
|
23.2 M | - | -4.14 % | $ 702 M | USA |
 |
Dynatronics Corporation
DYNT
|
-1.97 M | - | 14.99 % | $ 929 K | USA |
 |
Soliton, Inc.
SOLY
|
-14.1 M | - | -1.42 % | $ 435 M | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
88.4 K | - | -1.98 % | $ 98.3 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
-8.53 M | - | 0.03 % | $ 1.58 B | Israel |
 |
Misonix, Inc.
MSON
|
-15.9 M | - | - | $ 462 M | USA |
 |
Neovasc
NVCN
|
-31.1 M | - | - | $ 111 M |  Canada |
 |
GBS
GBS
|
-9.67 M | - | -0.57 % | $ 7.12 M | USA |
 |
Intersect ENT, Inc.
XENT
|
-64.8 M | - | - | $ 955 M | USA |
 |
InMode Ltd.
INMD
|
113 M | $ 13.79 | -1.11 % | $ 1.09 B | Israel |
 |
Eargo
EAR
|
-106 M | - | - | $ 10.2 M | USA |
 |
Electromed
ELMD
|
10.7 M | $ 27.84 | 0.04 % | $ 235 M | USA |
 |
Second Sight Medical Products
EYES
|
-24.3 M | - | -0.97 % | $ 54.4 M | USA |
 |
Align Technology
ALGN
|
753 M | $ 165.75 | -3.35 % | $ 12.4 B | USA |
 |
Avinger
AVGR
|
-16.3 M | - | -20.74 % | $ 369 K | USA |
 |
ClearPoint Neuro
CLPT
|
-18.8 M | $ 13.82 | -5.67 % | $ 374 M | USA |
 |
FONAR Corporation
FONR
|
9.84 M | $ 18.68 | 0.24 % | $ 122 M | USA |
 |
IRadimed Corporation
IRMD
|
22.8 M | $ 102.68 | 0.67 % | $ 1.3 B | USA |
 |
Integer Holdings Corporation
ITGR
|
319 M | $ 84.87 | -1.06 % | $ 2.85 B | USA |
 |
Invacare Corporation
IVC
|
-65 M | - | - | $ 24.7 M | USA |
 |
LivaNova PLC
LIVN
|
154 M | $ 62.45 | 0.55 % | $ 3.39 B |  Britain |
 |
Globus Medical
GMED
|
420 M | $ 92.68 | -0.85 % | $ 12.6 B | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
70.8 M | $ 11.98 | -3.51 % | $ 923 M | USA |
 |
Aziyo Biologics
AZYO
|
-26.8 M | - | 1.37 % | $ 20.5 M | USA |
 |
Pulmonx Corporation
LUNG
|
-56.6 M | $ 1.78 | 0.28 % | $ 69.6 M | USA |